Michael James Gagliardo, MD in Clifton Heights, PA - Medicare Family Practice

Michael James Gagliardo, MD is a medicare enrolled "Family Medicine" physician in Clifton Heights, Pennsylvania. He graduated from medical school in 1982 and has 42 years of diverse experience with area of expertise as Family Practice. His current practice location is 201 West Brook Dr, Clifton Heights, Pennsylvania. You can reach out to his office (for appointments etc.) via phone at (610) 623-0600.

Michael James Gagliardo is licensed to practice in Pennsylvania (license number MD035945E) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1407988843.

Contact Information

	Michael James Gagliardo, MD
	201 West Brook Dr, Clifton Heights, PA 19018
	(610) 623-0600
	(610) 623-0970

Physician's Profile

Full Name	Michael James Gagliardo
Gender	Male
Speciality	Family Practice
Experience	42 Years
Location	201 West Brook Dr, Clifton Heights, Pennsylvania
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Michael James Gagliardo graduated from medical school in 1982

NPI Data:

NPI Number: 1407988843
Provider Enumeration Date: 03/12/2007
Last Update Date: 11/27/2007

Medicare PECOS Information:

PECOS PAC ID: 3375633852
Enrollment ID: I20071220000476

Medical Identifiers

Medical identifiers for Michael James Gagliardo such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1407988843	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Q00000X	Family Medicine	MD035945E (Pennsylvania)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Mercy Home Health	Springfield, PA	Home health agency
Delaware County Memorial Hospital	Drexel hill, PA	Hospital
Main Line Hospital Lankenau	Wynnewood, PA	Hospital
Crozer Chester Medical Center	Upland, PA	Hospital
Riddle Memorial Hospital	Media, PA	Hospital

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Michael James Gagliardo is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Michael James Gagliardo, MD 201 West Brook Drive, Clifton Heights, PA 19018 Ph: (610) 623-0600	Michael James Gagliardo, MD 201 West Brook Dr, Clifton Heights, PA 19018 Ph: (610) 623-0600

News Archive

Scientists at Seattle conference discuss progress, obstacles in fight against HIV/AIDS

"Scientists, stymied for decades by the complexity of the human immunodeficiency virus, are making progress on several fronts in the search for a cure for HIV infections," but "a major stumbling block is the fact that HIV lies low in pools or reservoirs of latent infection that even powerful drugs cannot reach, scientists told the Conference on Retroviruses and Opportunistic Infections, one of the world's largest scientific meetings on HIV/AIDS," in Seattle last week, Reuters reports.

Concerns over potential health risks of using e-cigarettes gaining momentum

With sales of electronic cigarettes, or "e-cigarettes," on the rise and expected to hit $1.5 billion this year, concerns over potential health risks of using the trendy devices are also gaining momentum and political clout. An article in Chemical & Engineering News, the weekly magazine of the American Chemical Society, delves into what scientists and regulators are doing about e-cigarettes, which are now being cleverly marketed under more appealing names such as hookah pens and vape pipes.

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea Therapeutics International, Ltd. announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of NORTHERA™, an oral synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease.

Targeted therapy improves disease-free survival in patients with early-stage NSCLC

According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.

Michael James Gagliardo, MD - Medicare Family Practice in Clifton Heights, PA